Straits Times Index
3,325.41 +11.27 (+0.34%) Nikkei
39,173.15 +368.50 (+0.95%) Hang Seng
17,998.49 -29.22 (-0.16%) FTSE 100
8,281.55 0.00 (0.00%) Bitcoin USD
61,113.10 -1,229.58 (-1.97%) CMC Crypto 200
1,268.38 +19.26 (+1.54%)
APLS Jun 2024 22.500 put
| Previous close | 0.2800 |
| Open | 0.2800 |
| Bid | 0.0000 |
| Ask | 0.6000 |
| Strike | 22.50 |
| Expiry date | 2024-06-21 |
| Day's range | 0.2800 - 0.2800 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
Simply Wall St.Investors might be losing patience for Apellis Pharmaceuticals' (NASDAQ:APLS) increasing losses, as stock sheds 6.3% over the past week
While Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS ) shareholders are probably generally happy, the stock hasn't had...
ZacksApellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
GlobeNewswireSYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpointData presented at the Clinical Trials at the Summit Meeting WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that SYFOVRE® (pegcetacoplan injection) preserved visual function at 36 months in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). These positive data from the GALE long-term ext
